David Natan - 26 Feb 2025 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Reporting relationship: Director
Issuer ticker: CYCC
Reported as of: 26 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2025, 16:48:59 UTC
Prior SEC filing: 07 Jan 2025
Next SEC filing: 14 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ David Natan

Key filing fact

David Natan filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 28 Feb 2025.

Key facts

This page summarizes David Natan's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2025, 16:48.

Change

Previous filing in this sequence was filed on 07 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYCC transaction Derivative

Non-Qualified Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +700,000
Change %
Price: $0.000000
Shares after: 700,000
Date: 26 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 700,000
Exercise price: $0.3300
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.

Footnote F2

Includes shares of Common Stock previously reported in Table I of the Reporting Person's Form 4 filed on January 7, 2025, which were not issued by the Company and are being replaced with the option grant reported in this Form 4.